PROGNYX

Home/The Watchtower

From the Watchtower

Oncology intelligence, in the open.

Oncology competitive-intelligence briefings: trials, readouts, FDA moves and deals, traced to the primary record and published as the field moves.

Each briefing starts from primary sources and passes a separate audit; every fact traces to a document you can open. See the method · Oncology competitive intelligence

The Watchtower, by email

One email per briefing, nothing else. You confirm by clicking the link we send; you leave in one click.

Double opt-in. Never sold, no open tracking. Privacy.

Follow Prognyx on LinkedIn

Editorial illustration for the Prognyx briefing on ivonescimab, PD-1 x VEGF bispecific antibody Briefing ·

Summit's ivonescimab draws an FDA complete response letter in post-EGFR-TKI NSCLC

Editorial illustration for the Prognyx briefing on durvalumab (Imfinzi) plus enfortumab vedotin-ejfv, PD-L1 checkpoint inhibitor + Nectin-4 antibody-drug conjugate Briefing ·

FDA approves AstraZeneca's Imfinzi plus enfortumab vedotin for perioperative MIBC

Editorial illustration for the Prognyx briefing on belzutifan (WELIREG) plus lenvatinib, HIF-2α inhibitor + multi-targeted VEGFR tyrosine kinase inhibitor Briefing ·

Belzutifan plus lenvatinib wins positive EU CHMP opinion in kidney cancer

Merck's HIF-2alpha inhibitor combination clears Europe's scientific committee for ccRCC after PD-(L)1 therapy, on LITESPARK-011 progression-free survival data.

Editorial illustration for the Prognyx briefing on Cu-64 SAR-bisPSMA, PSMA PET imaging agent (copper-64 labeled) Briefing ·

Clarity's Cu-64 SAR-bisPSMA lands first PSMA-PET breakthrough designation

Clarity Pharmaceuticals says the FDA granted its copper-64 agent Cu-64 SAR-bisPSMA a breakthrough designation in biochemical recurrence, the first in PSMA PET imaging by the company's account, in a setting where at least seven tracers are already approved.

Editorial illustration for the Prognyx briefing on teclistamab-cqyv (TECVAYLI) plus talquetamab-tgvs (TALVEY); ramantamig, BCMA x CD3 bispecific + GPRC5D x CD3 bispecific; trispecific antibody (DARZALEX-based) Briefing ·

J&J's TECVAYLI-TALVEY Phase 3 cuts myeloma progression risk as early as second line

The company's ASH 2026 release reports Phase 3 data for the TECVAYLI-TALVEY bispecific pair reducing progression risk in relapsed myeloma as early as second line, plus first results for ramantamig, a trispecific built on DARZALEX.

Editorial illustration for the Prognyx briefing on nogapendekin alfa inbakicept-pmln (ANKTIVA) plus BCG, IL-15 superagonist (NK/T-cell activator) Briefing ·

ImmunityBio's ANKTIVA meets primary endpoint in BCG-naive bladder cancer trial

The IL-15 receptor agonist plus BCG beat BCG alone on the primary endpoint in the 370-patient randomized QUILT-2.005 trial, and ImmunityBio targets a Q4 2026 supplemental BLA to move into the first-line NMIBC population.

Editorial illustration for the Prognyx briefing on pasritamig plus JNJ-9401, KLK2 x CD3 bispecific + PSMA x CD3 bispecific Briefing ·

J&J reports 73% PSA response for pasritamig + JNJ-9401 bispecific prostate combo

Editorial illustration for the Prognyx briefing on brenetafusp plus tebentafusp-tebn (KIMMTRAK), PRAME x CD3 bispecific + gp100 x CD3 bispecific (ImmTAC) Briefing ·

Immunocore pairs brenetafusp with Kimmtrak in metastatic uveal melanoma

Editorial illustration for the Prognyx briefing on amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO), EGFR x MET bispecific antibody Briefing ·

Rybrevant Faspro wins accelerated FDA approval in second-line head and neck cancer

Accelerated approval covers patients whose disease progressed after platinum chemotherapy and a PD-(L)1 inhibitor, on a 42% response rate (95% CI 32-52%) in 102 patients.

Editorial illustration for the Prognyx briefing on loncastuximab tesirine (ZYNLONTA) plus glofitamab, CD19 antibody-drug conjugate + CD20 x CD3 bispecific antibody Briefing ·

ZYNLONTA plus glofitamab posts 88.7% response rate in relapsed DLBCL before ASH

Editorial illustration for the Prognyx briefing on HT-001, cancer treatment-related skin toxicity Briefing ·

Hoth ends HT-001 skin-toxicity trial early, seeks FDA feedback on Phase 3

Per a company release, Hoth's topical gel HT-001 showed strong interim efficacy in EGFR-inhibitor skin toxicity; the biotech now runs as a Rocket One subsidiary after May's pivot to AI and defense.

Editorial illustration for the Prognyx briefing on etentamig, BCMA x CD3 bispecific antibody Briefing ·

AbbVie files FDA application for etentamig, its BCMA bispecific for myeloma

AbbVie submitted a BLA on 27 October 2026 for etentamig in relapsed/refractory multiple myeloma, a class already served by three marketed bispecifics.

Editorial illustration for the Prognyx briefing on amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO), EGFR x MET bispecific antibody Briefing ·

J&J's RYBREVANT FASPRO posts 77% response rate in first-line head and neck cancer

J&J's subcutaneous EGFR/MET regimen showed a confirmed 77% overall response rate in previously untreated advanced head and neck cancer, supporting an ongoing Phase 3 study.

Editorial illustration for the Prognyx briefing on pembrolizumab (Keytruda), PD-1 checkpoint inhibitor Briefing ·

Merck's pembrolizumab cuts progression risk 43% in dMMR endometrial cancer

Editorial illustration for the Prognyx briefing on talazoparib (Talzenna) plus enzalutamide, PARP inhibitor + androgen receptor inhibitor Briefing ·

FDA approves Pfizer's talazoparib-enzalutamide for HRR-mutant prostate cancer

The 26 October approval covers androgen pathway modulation-naive or -sensitive disease across 12 HRR genes, wider than AKEEGA's BRCA2-restricted combination label.

Editorial illustration for the Prognyx briefing on tarlatamab (Imdelltra) plus durvalumab (Imfinzi), DLL3 x CD3 bispecific T-cell engager + PD-L1 checkpoint inhibitor Briefing ·

Amgen's Imdelltra plus Imfinzi cuts death risk 58% in first-line ES-SCLC

Phase III DeLLphi-305 data, presented at ESMO and published in NEJM, cut the risk of death by 58% for the tarlatamab plus durvalumab first-line maintenance combination versus durvalumab alone in extensive-stage small cell lung cancer.

Editorial illustration for the Prognyx briefing on arcotatug tavatecan (CLDN18.2-ADC), Claudin 18.2 antibody-drug conjugate Briefing ·

Innovent's arcotatug tavatecan clears OS and PFS in Phase 3 gastric cancer at ESMO

Editorial illustration for the Prognyx briefing on pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev), PD-1 checkpoint inhibitor + Nectin-4 antibody-drug conjugate Briefing ·

Keytruda-Padcev wins EU approval for resectable bladder cancer, any cisplatin status

The European Commission's 21 October clearance makes pembrolizumab plus enfortumab vedotin, per Merck, the EU's first PD-1-inhibitor-plus-ADC perioperative regimen for muscle-invasive bladder cancer without a cisplatin-eligibility restriction.

Editorial illustration for the Prognyx briefing on dostarlimab (Jemperli), PD-1 checkpoint inhibitor Briefing ·

FDA accelerated approval: GSK's Jemperli, first immunotherapy for dMMR rectal cancer

Accelerated approval rests on the single-arm AZUR-1 trial, where 68% of evaluable patients reached a clinical complete response at 12 months by investigator read while the blinded primary endpoint sits at 47% and is still maturing [1][2].

Editorial illustration for the Prognyx briefing on RBS2418, ENPP1 inhibitor Briefing ·

Riboscience to present RBS2418's first overall-survival data at ESMO 2026

Riboscience says its ESMO 2026 poster will carry first Phase 1b overall-survival and immune-activation data for its lead oral ENPP1 inhibitor RBS2418, as monotherapy and in combination in advanced metastatic cancers including MSS colorectal cancer; the figures themselves are not yet public.

Editorial illustration for the Prognyx briefing on talquetamab (Talvey), GPRC5D x CD3 bispecific antibody Briefing ·

CHMP backs a label change for Janssen's myeloma bispecific Talvey

On 15 October 2026 the CHMP recommended a change to Talvey's EU marketing authorisation; the EMA record does not state what the change covers.

Editorial illustration for the Prognyx briefing on avutometinib plus defactinib (VS-6766/defactinib), RAF/MEK clamp + FAK inhibitor combination Briefing ·

Verastem's VS-7375 hits 50% response in second-line pancreatic cancer, Phase 3 next

Editorial illustration for the Prognyx briefing on nogapendekin alfa inbakicept-pmln (Anktiva), IL-15 superagonist (NK/T-cell activator) Briefing ·

FDA expands ImmunityBio's Anktiva label to papillary-only NMIBC

The 14 October approval adds high-grade papillary-only tumors to the Anktiva plus BCG label, a group ImmunityBio puts at roughly 85% of non-muscle invasive bladder cancer.

Editorial illustration for the Prognyx briefing on PRO-XTEN dual-masked T-cell engagers, T-cell engager (masked, tumor-activated) Briefing ·

Gilead pays Vir $90M upfront for three masked T-cell engagers in solid tumors

Gilead takes an exclusive license to three preclinical PRO-XTEN dual-masked T-cell engagers; Vir keeps discovery and is eligible for up to $135M upfront and near-term, plus up to $1.74B in later milestones.